ABBV-519 Study for Lupus or Rheumatoid Arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old
- You have SLE or RA diagnosed by specific medical criteria and confirmed with blood tests
- Your disease is not well-controlled with at least one prior treatment you've taken for 3+ months
- Your B-cell count (a type of immune cell) is at least 50 cells/mcL
- You do not have uncontrolled high blood pressure or a history of serious infection
- You do not have brain or nervous system involvement from your lupus (if you have SLE)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
This study tests a new drug called A-319 for people whose lupus (SLE) is active or hasn't improved with current treatments. The goal is to see if A-319 can help control lupus better.
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
This study tests an investigational drug called LY4298445 in healthy people and in people with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). It aims to see if the drug is safe and how the body handles it.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.